UNC13A modulator therapy(Maze Therapeutics)

N/A

Report date: 2024/10/11 15:34:50

Base Information

Drug NameUNC13A modulator therapy(Maze Therapeutics)
Drug Alias NameN/A
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Oligonucleotide antisense
Mechanisms of ActionUnc-13 Homolog A modulators
TargetsUnc-13 Homolog A
Therapy Area/IndicationsAmyotrophic Lateral Sclerosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesMaze Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesTrace Neuroscience IncMaze Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAmyotrophic Lateral Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A